[IL-6 blockade], PMID: 27311186
A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection, PMID: 33443079
A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis, PMID: 28926467
Anti-cytokines in the treatment of cancer cachexia, PMID: 30180740
Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism, PMID: 34153143
Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial, PMID: 30635033
Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis, PMID: 31272807
Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis, PMID: 29244162
Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review, PMID: 30328022
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update, PMID: 28264816
From mechanism to therapies in systemic lupus erythematosus, PMID: 28118202
IL-6 Directed Therapy in Transplantation, PMID: 34099967
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future, PMID: 25648633
Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients, PMID: 33688459
Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities, PMID: 28707587
Interleukin-6 blocking agents for treating COVID-19: a living systematic review, PMID: 33734435
Interleukin-6 inhibition in the management of non-infectious uveitis and beyond, PMID: 31523783
New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatment, PMID: 33315763
Outpatient management of kidney transplant recipients with suspected COVID-19-Single-center experience during the New York City surge, PMID: 32578324
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis, PMID: 32381564
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis, PMID: 28579757
Proposal for a new nomenclature of disease-modifying antirheumatic drugs, PMID: 24072562
Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology, PMID: 29185959
Rheumatoid arthritis: new monoclonal antibodies, PMID: 29771256
Role of monoclonal antibody drugs in the treatment of COVID-19, PMID: 33083387
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial, PMID: 33115543
Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report, PMID: 32563584
Targeting interleukin-6 for noninfectious uveitis, PMID: 26392750
The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis, PMID: 27059799
The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study, PMID: 26138593
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer, PMID: 30372844
Targeting IL-6 in antibody-mediated kidney transplant rejection., PMID:40357502
[The highlights of dialysis in 2024]., PMID:40208672
Effects of Clazakizumab on Anemia and Iron Metabolism in Patients with Kidney Failure., PMID:39908111
Network meta-analysis of pharmacological treatment for antibody-mediated rejection after organ transplantation., PMID:39726594
New Therapies for Highly Sensitized Patients on the Waiting List., PMID:38995690
Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial., PMID:38961226
Granulomatous Tubulointerstitial Nephritis in a Kidney Allograft: Treatment with Interleukin-6 Receptor Antagonist Stabilises Kidney Function., PMID:38929956
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial., PMID:38796655
Advances in desensitization for human leukocyte antigen incompatible kidney transplantation., PMID:38088373
Chronic Active Antibody-mediated Rejection: Opportunity to Determine the Role of Interleukin-6 Blockade., PMID:37941113
Interleukin-6 blocking agents for treating COVID-19: a living systematic review., PMID:37260086
Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design., PMID:36550562
Importance of IL-6 inhibition in prevention and treatment of antibody-mediated rejection in kidney allografts., PMID:36453709
Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10., PMID:36382130
[Improving access to kidney transplantation for highly sensitized patients: What place for IL-6 pathway blockade in desensitization protocols?]., PMID:36328901
Investigational drugs for the treatment of kidney transplant rejection., PMID:36175360
Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena., PMID:35969004
Drug discovery in spinal cord injury-induced osteoporosis: a text mining-based study., PMID:35957736
Pharmacotherapeutic options for the prevention of kidney transplant rejection: the evidence to date., PMID:35835450
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials., PMID:35715978
A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation., PMID:35583232
Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts., PMID:35497778
Disparities in Access to Preemptive Repeat Kidney Transplant: Still Missing the Mark?, PMID:35368561
Anti-Interleukin 6 Therapeutics for Chronic Antibody-Mediated Rejection In Kidney Transplant Recipients., PMID:34981708
Clazakizumab for desensitization in highly sensitized patients awaiting transplantation., PMID:34910841
Tocilizumab and Desensitization in Kidney Transplant Candidates: Personal Experience and Literature Review., PMID:34640377
Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism., PMID:34153143
IL-6 Directed Therapy in Transplantation., PMID:34099967
Interleukin-6 blocking agents for treating COVID-19: a living systematic review., PMID:33734435
Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients., PMID:33688459
A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection., PMID:33443079
New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatment., PMID:33315763
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial., PMID:33115543
Role of monoclonal antibody drugs in the treatment of COVID-19., PMID:33083387
Outpatient management of kidney transplant recipients with suspected COVID-19-Single-center experience during the New York City surge., PMID:32578324
Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report., PMID:32563584
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis., PMID:32381564
Interleukin-6 inhibition in the management of non-infectious uveitis and beyond., PMID:31523783
Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis., PMID:31272807
Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial., PMID:30635033
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer., PMID:30372844
Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review., PMID:30328022
Anti-cytokines in the treatment of cancer cachexia., PMID:30180740
Rheumatoid arthritis: new monoclonal antibodies., PMID:29771256
Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis., PMID:29244162
Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology., PMID:29185959
A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis., PMID:28926467
Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities., PMID:28707587
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis., PMID:28579757
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update., PMID:28264816
For research use only. Not for human or drug use.
